Gami­da Cell prices its fol­low-on pub­lic of­fer­ing at $20M; Rally­bio touts Phase Ib da­ta for mon­o­clon­al an­ti­body

While Gami­da Cell is still charg­ing its way to­ward ap­proval for its ther­a­pies with new CEO Abi­gail Jenk­ins in place, it’s look­ing to gar­ner a lit­tle more cash.

The com­pa­ny an­nounced on Wednes­day that it will be of­fer­ing up over 12 mil­lion shares and ex­pect­ing pro­ceeds of an es­ti­mat­ed $20 mil­lion. The of­fer is ex­pect­ed to close on Sept. 30. Ac­cord­ing to Gami­da Cell, it plans to use the cash to help with the po­ten­tial launch of its omidu­bi­cel ther­a­py if it gets ap­proval. Omidu­bi­cel has a PDU­FA date set for Jan. 30, 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER